INTRODUCTION

Secukinumab (brand name Cosentyx) is a fully human IgG1/κ monoclonal antibody that binds to the interleukin-17A (IL-17A) to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Secukinumab is used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis.

RGBiotech offers Secukinumab expression plasmid vector. This plasmid vector is designed for expressing Secukinumab in mammalian expression system such as HEK293 or Chinese hamster ovary (CHO) cell line.

PRODUCT INFORMATION

Item No.: PPBD-168
Shipping: Lyophilized plasmid, or liquid plasmid, or plasmids on filter paper
Storage: -20 °C or 4°C according to instruction
Plasmid Backbone: Expression plasmid, flexible options, custom available
Quality Control: Sequencing validation

DRUG INFORMATION

Generic Name: Secukinumab
Brand Name(s): Cosentyx
Classification: Monoclonal antibody (mAb)
Target: IL17A, interleukin 17A, IL17; CTLA8; IL-17; ILA17; CTLA-8; IL-17A
Amino Acid Sequence: Identical to DB09029

PROTOCOL FOR PLASMID RECOVERY FROM FILTER PAPER

REFERENCE

[1] Jaleel T, Elmets C, Weinkle A, Kassira S, Elewski B. Secukinumab (AIN-457) for the treatment of Psoriasis. Expert Rev Clin Pharmacol. 2016;9(2):187-202.

[2] Roman M, Madkan VK, Chiu MW. Profile of secukinumab in the treatment of psoriasis: current perspectives. Ther Clin Risk Manag. 2015 Dec 2;11:1767-77.

Contact Us